Fig. 2.

Time from anti-CD38 antibody administration to vaccine and S-IgG response. Patients with MM without anti-CD38 antibody and with anti-CD38 antibody within 6 months before first vaccine showed 93.0% and 82.3% in seropositivity and 47.0% and 26.6% in clinically protective titer (Left). Patients with anti-CD38 antibody administration within 30 days and 31 to 180 days before their first vaccine showed 82.5% and 81.3% in seropositivity and 23.8% and 37.5% in clinically protective titer, respectively (Right). Patients who received anti-CD38 antibody 6 months or over before first vaccine were included in “w/o anti-CD38 antibody” group. Significance of differences between the indicated groups was assessed using the Mann–Whitney U test or Kruskal–Wallis test, respectively. Asterisks denote significant changes (*0.01 ≤ p < 0.05 and **0.001 ≤ p < 0.01)